FPWR maintains the latest clinical trial information so that you can stay abreast of trial opportunities. Some trials require in-person visits while others can be completed remotely. Some trials are testing new drugs while others are intervention (non-drug) or natural history studies. Details of...
Source: FPWR Blog
|
Published: October 10 2024 - 10:30 AM
As the COVID-19 pandemic continues to evolve, researchers are working hard to understand how the virus affects individuals with Prader-Willi syndrome (PWS). A recent study by FPWR Grant Recipient Dr. James Luccarelli and colleagues from the Massachusetts General Hospital/Harvard Medical School, as...
Source: FPWR Blog
|
Published: September 9 2024 - 10:00 AM
The FDA has announced its plan to conduct an Advisory Committee Meeting as part of its review of Soleno Therapeutics' DCCR New Drug Application. The FDA convenes Advisory Committees to provide independent expert advice that contributes to the agency's regulatory decision-making. As part of the...
Source: FPWR Blog
|
Published: September 9 2024 - 05:15 AM
70% of cases of Prader-Willi syndrome are associated with a “deletion” of 5,000–6,000 missing base pairs (bp) of DNA on the paternally inherited copy of chromosome 15. What are the biological consequences of the larger 6,000-bp deletion (typically called “Type 1” or T1 in the context of PWS) versus...
Source: FPWR Blog
|
Published: August 8 2024 - 09:15 AM
If your loved one with PWS struggles with daytime sleepiness, you may be interested in learning more about TEMPO, a phase 3 study of Pitolisant, now enrolling volunteers with PWS ages 6 to 65 years old. This study will evaluate the efficacy of Pitolisant in treating excessive daytime sleepiness in...
Source: FPWR Blog
|
Published: June 6 2024 - 03:24 PM
